P
Paneez Khoury
Researcher at National Institutes of Health
Publications - 76
Citations - 1953
Paneez Khoury is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Medicine & Eosinophilia. The author has an hindex of 17, co-authored 40 publications receiving 1161 citations. Previous affiliations of Paneez Khoury include University of Illinois at Chicago & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Michael E. Wechsler,Praveen Akuthota,David Jayne,Paneez Khoury,Amy D. Klion,Carol A. Langford,Peter A. Merkel,Frank Moosig,Ulrich Specks,Maria C. Cid,Raashid Luqmani,Judith Brown,Stephen Mallett,Richard Philipson,Steve Yancey,Jonathan Steinfeld,Peter F. Weller,Gerald J. Gleich +17 more
TL;DR: In participants with eosinophilic granulomatosis with polyangiitis, mepolizumab resulted in significantly more weeks in remission and a higher proportion of participants in remission than did placebo, thus allowing for reduced glucocorticoid use.
Journal ArticleDOI
Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis
Evan S. Dellon,Kathryn A. Peterson,Joseph A. Murray,Gary W. Falk,Nirmala Gonsalves,Mirna Chehade,Robert M. Genta,John Leung,Paneez Khoury,Amy D. Klion,Sabine Hazan,Michael F. Vaezi,Adam C. Bledsoe,Sandy R. Durrani,Chao Wang,Camilla Shaw,Alan T. Chang,Bhupinder Singh,Amol P. Kamboj,Henrik S. Rasmussen,Marc E. Rothenberg,Ikuo Hirano +21 more
TL;DR: In patients with eos inophilic gastritis or duodenitis, AK002 reduced gastrointestinal eosinophils and symptoms.
Journal ArticleDOI
Eosinophils in vasculitis: characteristics and roles in pathogenesis
TL;DR: This Review focuses on the aspects of eosinophil biology most relevant to the pathogenesis of vasculitis and provides an update of current knowledge regarding the role of eOSinophils in EGPA and other vasculitides.
Journal ArticleDOI
Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome.
Fei Li Kuang,Fanny Legrand,Michelle Makiya,JeanAnne Ware,Lauren Wetzler,Tom Brown,Tamika Magee,Brent Piligian,Pryscilla Yoon,Jamie H. Ellis,Xiaoping Sun,Sandhya R. Panch,Astin Powers,Hawwa Alao,Sheila Kumar,Martha Quezado,Li Yan,Nancy Raitano Lee,Roland Kolbeck,Paul Newbold,Mitchell Goldman,Michael P. Fay,Paneez Khoury,Irina Maric,Amy D. Klion +24 more
TL;DR: Patients with PDGFRA‐negative hypereosinophilic syndrome who received benralizumab for 12 weeks had lower absolute eos inophil counts than those who received placebo, and only clinical disease subtype appeared to be associated with the initial response or relapse.
Journal ArticleDOI
Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
Jonathan Steinfeld,Eric S. Bradford,Judith Brown,Stephen Mallett,Steven W. Yancey,Praveen Akuthota,Maria C. Cid,Gerald J. Gleich,David Jayne,Paneez Khoury,Carol A. Langford,Peter A. Merkel,Frank Moosig,Ulrich Specks,Peter F. Weller,Michael E. Wechsler +15 more
TL;DR: When a comprehensive definition of clinical benefit was applied to data from a randomized controlled trial, 78% to 87% of patients with EGPA experienced benefit with mepolizumab.